miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer-Reference-Cited by-同舟云学术

miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer

Published:2019-10-10 Issue:12 Volume:23 Page:8114-8127
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cell Mol Med

Author:

Tang Hailin¹,Song Cailu¹,Ye Feng¹,Gao Guanfeng¹,Ou Xueqi¹,Zhang Lijuan¹,Xie Xinhua¹^ORCID,Xie Xiaoming¹

Affiliation:

1. State Key Laboratory of Oncology in South China Department of Breast Oncology Collaborative Innovation Center of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.14681

Reference53 articles.

1. Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

3. The ERBB network: at last, cancer therapy meets systems biology

4. Optical Metabolic Imaging Identifies Glycolytic Levels, Subtypes, and Early-Treatment Response in Breast Cancer

5. Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. All-in-One Fusogenic Nanoreactor for the Rapid Detection of Exosomal MicroRNAs for Breast Cancer Diagnosis;ACS Nano;2024-09-09

2. BRCA Mutations and MicroRNA Expression Patterns in the Peripheral Blood of Breast Cancer Patients;ACS Omega;2024-04-03

3. Unveiling the mechanisms and challenges of cancer drug resistance;Cell Communication and Signaling;2024-02-12

4. Magnolol regulates miR-200c-3p to inhibit epithelial–mesenchymal transition and retinoblastoma progression by modulating the ZEB1/E-cadherin axis in vitro and in vivo;Phytomedicine;2023-02

5. Perspectives of using microRNA-loaded nanocarriers for epigenetic reprogramming of drug resistant colorectal cancers;Seminars in Cancer Biology;2022-11